The co-leaders of the financing were Novo Holdings and Bpifrance, with other investments from Invus, UI Investissement, Seroba Life Sciences, Fund+, Kurma Partners, Omnes Capital, and Turenne Capital.
The $94 million (€90 million) Series A funding will be used to support the development of the company’s pipeline of nCycles, oral macrocycle drugs that will be focused on validated biologic targets.
With the DKK 8.5 billion (US$1.2 billion) investment, Novo Nordisk will build a new modular and flexible production facility in Odense, Denmark, to produce multiple products for rare diseases.
Lilly will expand its recently acquired manufacturing facility in Wisconsin with a $3 billion investment, and Amgen will expand its North Carolina facility with a $1 billion investment.